(12) CORRECTED EUROPEAN PATENT APPLICATION

(15) Correction information:

Corrected version no 1 (W1 A1) Corrections, see

Bibliography INID code(s) 27

(48) Corrigendum issued on:

26.10.2011 Bulletin 2011/43

(43) Date of publication:

13.07.2011 Bulletin 2011/28

(21) Application number: 10012259.7

(22) Date of filing: 03.10.2006

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated Extension States:

AL BA HR MK RS

- (30) Priority: 25.10.2005 PCT/IB2005/003568
- (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: 06842331.8 / 1 979 478
- (27) Previously filed application: 03.10.2006 PCT/IB20/06003893

(51) Int Cl.:

C12N 9/22 (2006.01) C12N 15/64 (2006.01) C12N 15/79 (2006.01) C12N 15/55 (2006.01) C12N 15/10 (2006.01) C12N 15/82 (2006.01)

- (71) Applicant: Cellectis
 93235 Romainville Cedex (FR)
- (72) Inventor: Paques, Frédéric 92340 Bourg-La-Reine (FR)
- (74) Representative: Noel, Chantal Odile et al Cabinet Orès
 36, rue de St Pétersbourg
 75008 Paris (FR)

Remarks:

- •Claims filed after the date of filing of the application (Rule 68(4) EPC).
- •This application was filed on 30-09-2010 as a divisional application to the application mentioned under INID code 62.
- (54) Laglidadg homing endonuclease variants having mutations in two functional subdominants und use thereof
- (57) A LAGLIDADG homing endonuclease variant, having mutations in two separate subdomains, each binding a distinct part of a modified DNA target half-site, said LAGLIDADG homing endonuclease variant being able to cleave a chimeric DNA target sequence compris-

ing the nucleotides bound by each subdomain.

Use of said herodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy.

EP 2 343 368 A8